US Treasury 3 Year Note ETF UTRE 深 沪
等待开盘 10-24 09:30:00 美东时间
49.985
-0.070
-0.14%
华盛通- 最 高49.985
- 今 开50.055
- 成交量 23股
- 最 低 49.985
- 昨 收 50.055
- 总市值 1049.69万
- 52周最高 50.07
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 47.1676
- 委 比 75.00%
- 总股本 21.00万
- 历史最高 50.07
- 量 比 0.01
- 振 幅 0.00%
- 历史最低 44.3275
- 每 手 1
- 风险率 0.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Merus Reveals Petosemtamab In Metastatic Colorectal Cancer Abstract Selected For Plenary Session Oral Presentation At The AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics, Being Held In Boston, Massachusetts On October 22-26, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific
10-14 00:04
XOMA Royalty And LAVA Therapeutics Announced The Extension Of The Expiration Of The Tender Offer To Purchase All Outstanding Shares Of Common Shares Of LAVA
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today
10-03 04:47
Liquidia Analysts Raise Their Forecasts Following Q2 Results
Liquidia Corporation (NASDAQ:LQDA) reported a loss for the second quarter on Tu...
08-14 02:51
In July And August Of 2025, Liquidia Analyzed Interim Data From The 52-week, Prospective, Open-label ASCENT Study Which Fully Enrolled 54 Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Safety data and observed exploratory efficacy data was summarized for Week 8 and Week 16 timepoints. The tolerability profile of YUTREPIA in PH-ILD was consistent with initial observations in the first 20 patients
08-12 18:36
Earnings Preview For Liquidia
Liquidia (NASDAQ:LQDA) is gearing up to announce its quarterly earnings on Tues...
08-11 23:04
Liquidia Begins Shipping Newly Approved Yutrepia for Rare Lung Diseases Just Days After FDA OK
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial
06-02 18:34
Breaking Down Liquidia: 12 Analysts Share Their Views
During the last three months, 12 analysts shared their evaluations of Liquidia ...
05-28 21:00
Liquidia Technologies Gains FDA Approval for YUTREPIA
Liquidia Technologies ( ($LQDA) ) has provided an announcement. On May 23, 2025...
05-24 04:52
Merus Reports Interim Phase 2 Data Showing 63% Response Rate And 79% 12-Month Overall Survival For Petosemtamab Plus Pembrolizumab In Ongoing Trial, To Be Presented At ASCO 2025 With Conference Call Scheduled For May 22
- 63% response rate observed among 43 evaluable patients- 79% overall survival rate at 12-months; 9 months median progression-free survival- Conference Call on Thursday, May 22 at 5:30 p.m.
05-23 05:36
United Therapeutics Corporation Filed A Complaint On May 9, 2025, In The U.S. District Court For The Middle District Of North Carolina Against Liquidia Alleging Infringement Of U.S. Patent No. 11,357,782.
Additionally, the complaint seeks to enjoin Liquidia from commercializing YUTREPIA (treprostinil) inhalation powder if approved by the U.S. Food and Drug Administration (FDA) to treat pulmonary arterial hypertension
05-12 18:13
